Assessing the Uptake of Core Outcome Sets in Randomized Controlled Trials for Inflammatory Bowel Disease: A Cross Sectional Study

Authors

  • Alexandra Shumard
  • Adam Khan Oklahoma State University Osteopathic Medical Student
  • Trevor Magee
  • Jay Modi Oklahoma State University Osteopathic Medical Student
  • Shaelyn Ward Oklahoma State University Osteopathic Medical Student
  • Kimberly Magana Oklahoma State University Osteopathic Medical Student
  • Garrett Jones Oklahoma State University Osteopathic Medical Student
  • Kyle Fitzgerald Oklahoma State University Osteopathic Medical Student
  • Griffin Hughes Oklahoma State University Osteopathic Medical Student
  • Alicia Ford Oklahoma State University Osteopathic Medical Student
  • Matt Vassar

Abstract

Abstract

 

Background

Increasing prevalence and significant medical expenses associated with Inflammatory Bowel Disease (IBD) necessitate high-quality clinical research to evaluate treatment effectiveness. Randomized control trials (RCTs) provide robust evidence, but the diversity of outcomes used in these trials poses challenges in summarizing outcomes for systematic reviews. Core Outcome Sets (COS) were established to improve the comparability of outcomes across studies. The aim of this study is to examine the uptake of the COS for IBD within clinical trials.

 

Methods

This cross-sectional analysis involved screening ClinicalTrials.gov for RCTs evaluating outcomes in patients with IBD. We extracted information on the four outcome domains —  (1) symptoms, function, and quality of life; (2) disutility of care; (3) healthcare utilization; and (4) survival and disease control — and trial characteristics. Extraction was performed in a masked, duplicate manner.

 

Results

The initial search identified 3,205 trials from ClinicalTrials.gov, and after exclusions, the final sample included 177 clinical trials for analysis. The uptake of COS over time was not statistically significant. The most frequently reported outcomes were change in bowel symptoms (88.1%, 156/177) and pain or discomfort (83.1%, 147/177). In contrast, no trial reported on colorectal cancer, only 1% (2/177) reported overall survival, and 8% (15/177) reported cause of death.

 

Conclusion

Our study revealed no increase in adherence to COS in IBD clinical trials, before or after the publication of the IBD COS. We recommend that trialists make efforts to implement COS in clinical trials to improve the standardization across studies in the field of IBD.

Downloads

Published

2024-12-12

Issue

Section

Medical